2025 Global Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 Global Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Cancer Immunotherapy Drug Discovery Outsourcing Market include Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), and Eurofins Scientific SE. These companies provide essential contract research organization (CRO) services that accelerate cancer immunotherapy drug development by offering expertise in target identification, preclinical research, and clinical trial management. For example, LabCorp expanded its cancer drug portfolio with the acquisition of OmniSeq®, enhancing its service capabilities. These leaders have significant presence in North America, the largest regional market, and are expanding activities globally, including Asia-Pacific, which is the fastest-growing region.
In addition to these four, other notable participants in the market include WuXi AppTec, Charles River Laboratories, and PerkinElmer, which also contribute to outsourcing solutions in cancer drug discovery. The market is witnessing strategic partnerships and advancements in technology, such as personalized cancer vaccines, immune checkpoint inhibitors, and oncolytic viral therapies, driving growth. North America dominates the market due to established healthcare infrastructure and biotech presence, while Asia-Pacific benefits from cost-effective services and regulatory compliance. The market size was valued around USD 1.5 billion in 2024 and is projected to grow at a CAGR near 9.8% to over USD 3 billion by 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Cancer Immunotherapy Drug Discovery Outsourcing Market include Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), and Eurofins Scientific SE. These companies provide essential contract research organization (CRO) services that accelerate cancer immunotherapy drug development by offering expertise in target identification, preclinical research, and clinical trial management. For example, LabCorp expanded its cancer drug portfolio with the acquisition of OmniSeq®, enhancing its service capabilities. These leaders have significant presence in North America, the largest regional market, and are expanding activities globally, including Asia-Pacific, which is the fastest-growing region.
In addition to these four, other notable participants in the market include WuXi AppTec, Charles River Laboratories, and PerkinElmer, which also contribute to outsourcing solutions in cancer drug discovery. The market is witnessing strategic partnerships and advancements in technology, such as personalized cancer vaccines, immune checkpoint inhibitors, and oncolytic viral therapies, driving growth. North America dominates the market due to established healthcare infrastructure and biotech presence, while Asia-Pacific benefits from cost-effective services and regulatory compliance. The market size was valued around USD 1.5 billion in 2024 and is projected to grow at a CAGR near 9.8% to over USD 3 billion by 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
